Product
PBFT02
1 clinical trial
2 indications
Indication
Frontotemporal DementiaIndication
Frontotemporal dementiaClinical trial
A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the Cisterna Magna of Adult Subjects With Frontotemporal Dementia and Mutations in the Progranulin GeneStatus: Recruiting, Estimated PCD: 2024-08-01